UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Annals of oncology, 2020-02, Vol.31 (2), p.191-201

2020

Volltextzugriff (PDF)

MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis

Oncogene, 2012-01, Vol.31 (4), p.458-468

2012

Volltextzugriff (PDF)

143O High anus preservation and low toxicity rates in a phase I trial of neoadjuvant bowel-sparing IMRT/bevacizumab/FOLFOX and TME for locally advanced rectal cancer

Annals of oncology, 2015-12, Vol.26, p.ix42-ix42

2015

Volltextzugriff (PDF)

Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver Through STAT3 Signaling Pathway

International journal of radiation oncology, biology, physics, 2009-12, Vol.75 (5), p.1545-1552

2009

Volltextzugriff (PDF)

Medulloblastoma in adults: Treatment outcome, relapse patterns, and prognostic factors

Strahlentherapie und Onkologie, 2012-10, Vol.188 (10), p.878-886

2012

Volltextzugriff (PDF)

Radiation-induced interleukin-6 expression through MAPK/p38/NF-kappaB signaling pathway and the resultant antiapoptotic effect on endothelial cells through Mcl-1 expression with sIL6-Ralpha

International journal of radiation oncology, biology, physics, 2009-12, Vol.75 (5), p.1553

2009

Volltextzugriff (PDF)

Phase-specific cone beam computed tomography reduces reconstructed volume loss of moving phantom

Strahlentherapie und Onkologie, 2012, Vol.188 (1), p.77-83

2012

Volltextzugriff (PDF)

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

Annals of oncology, 2022-09, Vol.33, p.S1422

2022

Volltextzugriff (PDF)

987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study

Annals of oncology, 2022-09, Vol.33, p.S1003-S1004

2022

Volltextzugriff (PDF)

512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC

Annals of oncology, 2023-11, Vol.34, p.S1668

2023

Volltextzugriff (PDF)

510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02)

Annals of oncology, 2023-11, Vol.34, p.S1666-S1667

2023

Volltextzugriff (PDF)

LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC

Annals of oncology, 2023-10, Vol.34, p.S1311-S1312

2023

Volltextzugriff (PDF)

6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407

Annals of oncology, 2021-12, Vol.32, p.S1376-S1377

2021

Volltextzugriff (PDF)

LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

Annals of oncology, 2022-11, Vol.33, p.S1561-S1562

2022

Volltextzugriff (PDF)

PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S36-S37

2023

Volltextzugriff (PDF)

EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S410-S411

2022

Volltextzugriff (PDF)

Gefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study

Annals of oncology, 2018-10, Vol.29, p.viii495-viii496

2018

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(5)
Oncology
(5)
Science & Technology
(5)
Humans
(4)
Medicine
(3)
Radiology, Nuclear Medicine & Medical Imaging
(3)
Radiotherapy
(3)
Animals
(2)
Body
(2)
Gene Amplification
(2)
Gene Expression
(2)
Imidazoles - Pharmacology
(2)
Male
(2)
Medicine & Public Health
(2)
Mice
(2)
Mice, Inbred C57bl
(2)
Nsclc
(2)
Organic Compounds
(2)
Original Article
(2)
Polymerase Chain Reaction
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis

143O High anus preservation and low toxicity rates in a phase I trial of neoadjuvant bowel-sparing IMRT/bevacizumab/FOLFOX and TME for locally advanced rectal cancer

Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver Through STAT3 Signaling Pathway

Medulloblastoma in adults: Treatment outcome, relapse patterns, and prognostic factors

Radiation-induced interleukin-6 expression through MAPK/p38/NF-kappaB signaling pathway and the resultant antiapoptotic effect on endothelial cells through Mcl-1 expression with sIL6-Ralpha

Phase-specific cone beam computed tomography reduces reconstructed volume loss of moving phantom

LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study

512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC

510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02)

LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407

LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)

EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

Gefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study

Suchergebnisse filtern